PATRICK DEVAL L - 14 Jun 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role
Director
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
14 Jun 2022
Net transactions value
$0
Form type
4
Filing time
16 Jun 2022, 16:46:00 UTC
Previous filing
15 Jun 2022
Next filing
17 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Award $0 +23,459 $0.000000 23,459 14 Jun 2022 Common Stock 23,459 $24.35 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date.

Remarks:

Exhibit 24 - Power of Attorney